Cargando...

Testosterone, HDL and cardiovascular risk in men: the jury is still out

“Even when reductions in HDL-cholesterol are observed as a consequence of androgen therapy, the implications for cardiovascular risk modification remain highly uncertain.”

Guardado en:
Detalles Bibliográficos
Publicado en:Clin Lipidol
Autores principales: Rubinow, Katya B, Page, Stephanie T
Formato: Artigo
Lenguaje:Inglês
Publicado: 2012
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4219622/
https://ncbi.nlm.nih.gov/pubmed/25379057
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/clp.12.38
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!